吉西他滨联合厄洛替尼对肺癌患者T细胞亚群及细胞因子的影响

Effects of Gemcitabine Combined with Erlotinib on T Cell Subsets and Cytokines in Patients with Lung Cancer

目的:探讨吉西他滨联合厄洛替尼对肺癌患者T细胞亚群及细胞因子的影响。方法:选取2017年1月至2018年1月上海长海医院收治的肺癌患者110例采用随机数字表法分为观察组与对照组,每组55例。对照组患者给予吉西他滨联合卡铂方案治疗,观察组患者在对照组的基础上联合厄洛替尼治疗。观察两组患者的近期疗效、T细胞亚群[T淋巴细胞(CD3+)、Th细胞(CD4+)、Ts细胞(CD8+)及CD4+/CD8+]水平、细胞因子[白细胞介素2(IL-2)、白细胞介素6(IL-6)、白细胞介素10(IL-10)及肿瘤坏死因子α(TNF-α)]水平及不良反应发生情况。结果:观察组患者的总有效率为96.36%(53/55),明显高于对照组的80.00%(44/55)差异有统计学意义(P<0.05)。治疗后,观察组患者CD3+、CD4+及CD4+/CD8+水平明显高于对照组,且CD8+水平明显低于对照组差异均有统计学意义(P<0.05)。治疗后,观察组患者IL-2水平明显高于对照组JL-6、IL-10及TNF-α水平明显低于对照组差异均有统计学意义(P<0.05)。观察组患者的不良反应发生率为9.09%(5/55),明显低于对照组的38.13%(21/55)差异有统计学意义(P<0.05)。结论:吉西他滨联合厄洛替尼治疗肺癌的效果较为理想,可有效改善患者T细胞亚群、细胞因子水平,且安全性较高,对于改善患者预后具有积极作用。

OBJECTIVE:To investigate the effects of gemcitabine combined with erlotinib on T cell subsets and cytokines in patients with lung cancer.METHODS:A total of 110 patients with lung cancer admitted into Shanghai Changhai Hospital from Jan.2017 to Jan.2018 were extracted to be divided into the observation group and the control group via the random number table,with 55 cases in each group.The control group was treated with gemcitabine combined with carboplatin,and the observation group was given erlotinib treatment on the basis of the control group.The short-term efficacy,T cell subsets[T lymphocytes(CD3^+),Th cells(CD4^+),Ts cells(CD8^+),and CD4^+/CD8^+],cytokine[interleukin 2(IL-2),interleukin 6(IL-6),interleukin 10(IL-10)and tumor necrosis factorα(TNF-α)]levels]and adverse drug reactions of two groups were observed.RESULTS:The total effective rate in the observation group was 96.36%(53/55),significantly higher than that in the control group(80.00%,44/55),with statistically significant difference(P<0.05).After treatment,the levels of CD3^+,CD4^+and CD4^+/CD8^+in the observation group were significantly higher than those in the control group,and the levels of CD8^+were significantly lower than those in the control group,with statistically significant differences(P<0.05).After treatment,the levels of IL-2 in the observation group were significantly higher than those in the control group,and the levels of IL-6,IL-10 and TNF-αwere significantly lower than those in the control group,the differences were statistically significant(P<0.05).The incidence of adverse drug reactions in the observation group was 9.09%(5/55),significantly lower than the control group 38.13%(21/55),and the difference was statistically significant(P<0.05).CONCLUSIONS:Gemcitabine combined with erotinib has significant effects in the treatment of lung cancer,which can effectively improve the T cell subsets and cytokine levels in patients with higher safety,and has positive effects on improving the prognosis of patients.